search
Back to results

Intracellular Phosphate Concentration Evolution During Hemodialysis by MR Spectroscopy (CIPHEMO)

Primary Purpose

End-Stage Renal Disease (ESRD)

Status
Completed
Phase
Not Applicable
Locations
France
Study Type
Interventional
Intervention
Phosphorus (31P) magnetic resonance spectroscopy
Hemodialysis
Sponsored by
Hospices Civils de Lyon
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional basic science trial for End-Stage Renal Disease (ESRD) focused on measuring ESRD, hemodialysis, phosphate, ATP, magnetic resonance spectroscopy

Eligibility Criteria

18 Years - 80 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Patient suffering from end-stage renal disease, treated by chronic hemodialysis since at less 6 months
  • Phosphatemia (at the start of the session) ≥ 1,5 mmol/L and ≤ 3 mmol/L
  • written consent signed

Exclusion Criteria:

  • Major subject protected by law
  • Prisoners or subjects who are involuntarily incarcerated
  • Denutrition (weight loss ≥ 5 kg in one months/10 kg in 6 months, Body Mass Index (BMI) ≤ 21 kg/m2, albuminemia ≤ 35 g/L)
  • Obesity (BMI ≥ 30 kg/m2)
  • Phosphatemia at the start of the dialysis < 1,5 mmol/L or > 3 mmol/L
  • Secondary hyperparathyroidism with parathormone (PTH) ≥ 1000 pg/mL
  • Adynamic osteopathy (PTH ≤ 50 pg/mL)
  • Hypoparathyroidism with a history of parathyroidectomy
  • Hemoglobin ≤ 100 g/L
  • Contraindication to heparin
  • Temporary vascular access
  • Contraindication to resonance magnetic spectroscopy (pacemaker or insulin pump, metallic valvular prosthesis, valvular prosthesis not compatible with resonance magnetic spectroscopy, dental appliance, intracerebral clip, claustrophobic subject).
  • Simultaneous participation to another research protocol
  • Patient not affiliated to a social security system

Sites / Locations

  • Service de Néphrologie Pavillon P, Hôpital E. Herriot

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

Patients suffering from ESRD treated by chronic hemodialysis

Arm Description

Patients aged from 18 to 80 years old, suffering from ESRD, treated by chronic hemodialysis since at least 6 months and whose phosphatemia at the beginning of HD sessions ranged from 1.5 to 3 mmol/L. Phosphorus (31P) magnetic resonance spectroscopy will be performed in these patients during hemodialysis in order to measure intracellular phosphate and ATP concentrations and intracellular pH evolution during hemodialysis.

Outcomes

Primary Outcome Measures

Change in phosphate intracellular concentration
Measurement of phosphate intracellular concentration evolution during a 4 hours hemodialysis (HD) session using phosphorus magnetic resonance spectroscopy.

Secondary Outcome Measures

Change in ATP intracellular concentration
Measurement of ATP intracellular concentration evolution during a 4 hours HD session using phosphorus magnetic resonance spectroscopy.
Change in intracellular pH
Measurement of intracellular pH evolution during a 4 hours HD session using phosphorus magnetic resonance spectroscopy. Intracellular pH will be calculated using the Henderson-Hasselbach formula: Ph = 6.75 + log (δ-3.27)/(5.69-δ), with δ being the difference (in parts per million) between inorganic phosphate (Pi) and phosphocreatine (PCr) resonance frequencies.
Change in phosphatemia
Measurement of intracellular pH evolution during a 4 hours HD session using phosphorus magnetic resonance spectroscopy. Intracellular pH will be calculated using the Henderson-Hasselbach formula: Ph = 6.75 + log (δ-3.27)/(5.69-δ), with δ being the difference (in parts per million) between Pi (inorganic phosphate) and PCr (phosphocreatine) resonance frequencies.
Calcium balance
Calcium balance will be measured using the formula: (Cae - Cab)(Ve - UF)+(Cae * UF), where Cae is the calcium in the effluent, Cab is the calcium in the dialysis solution, Ve is the volume of effluent, and UF is the ultrafiltration.

Full Information

First Posted
April 11, 2017
Last Updated
February 23, 2018
Sponsor
Hospices Civils de Lyon
search

1. Study Identification

Unique Protocol Identification Number
NCT03119818
Brief Title
Intracellular Phosphate Concentration Evolution During Hemodialysis by MR Spectroscopy
Acronym
CIPHEMO
Official Title
Intracellular Phosphate and Adenosine Triphosphate (ATP) Concentration Evolution by Magnetic Resonance (MR) Spectroscopy in Patients During Hemodialysis
Study Type
Interventional

2. Study Status

Record Verification Date
April 2017
Overall Recruitment Status
Completed
Study Start Date
June 14, 2017 (Actual)
Primary Completion Date
July 29, 2017 (Actual)
Study Completion Date
July 29, 2017 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Hospices Civils de Lyon

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
End-stage renal disease is associated with hyperphosphatemia due to a decrease of renal phosphate excretion. This hyperphosphatemia is associated with an increase of cardiovascular risk and mortality. Thus, three therapeutic options have been developed: dietary restriction, administration of phosphate binders and phosphorus clearance by hemodialysis (HD). During a standard HD session, around 600 to 700mg phosphate is removed from the plasma, whereas it contains only 90 mg inorganic phosphate (Pi); 85% of phosphate is stored in bones and teeth in hydroxyapatite form, 14% is stored in the intracellular space (90% organic phosphate and 10% Pi), and 1% remains in the extracellular space. Currently, the source of Pi cleared during HD remains to be determined. Phosphorus (31P) magnetic resonance spectroscopy allows reliable, dynamic and non-invasive measurements of phosphate intracellular concentration. The investigator's team recently published data obtained in anephric pigs, suggesting that phosphate intracellular concentration increases during a HD session. In parallel, we showed that ATP intracellular concentration decreased. These results suggest that the source of Pi cleared during HD could be located inside the cell. In this study, investigators will measure intracellular phosphate and ATP concentrations and intracellular potential of hydrogen (pH) evolution during hemodialysis in 12 patients suffering from end-stage renal disease by MR spectroscopy. If these results were confirmed in humans, it could explain, at least in part, HD intolerance in some patients and would lead to modify therapeutic approaches of hyperphosphatemia, for example, by modifying HD sessions time.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
End-Stage Renal Disease (ESRD)
Keywords
ESRD, hemodialysis, phosphate, ATP, magnetic resonance spectroscopy

7. Study Design

Primary Purpose
Basic Science
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
11 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Patients suffering from ESRD treated by chronic hemodialysis
Arm Type
Experimental
Arm Description
Patients aged from 18 to 80 years old, suffering from ESRD, treated by chronic hemodialysis since at least 6 months and whose phosphatemia at the beginning of HD sessions ranged from 1.5 to 3 mmol/L. Phosphorus (31P) magnetic resonance spectroscopy will be performed in these patients during hemodialysis in order to measure intracellular phosphate and ATP concentrations and intracellular pH evolution during hemodialysis.
Intervention Type
Device
Intervention Name(s)
Phosphorus (31P) magnetic resonance spectroscopy
Intervention Description
Phosphorus MR spectroscopy realized using a 3-Tesla MR imaging system. A twenty-cm circular surface coil will be set to the 31P resonance frequency and placed over the leg muscle region to obtain spectroscopy acquisitions. 31P MR spectra will be acquired before, during (every 160 seconds), and 30 minutes after dialysis. 31P MR system data will be analyzed using jMRUI Software. Five different peaks will be analyzed: inorganic phosphate, phosphocreatine, α-, β-, and γ-ATP.
Intervention Type
Other
Intervention Name(s)
Hemodialysis
Intervention Description
Hemodialysis realized using a 5008 generator, a portable plant, a FX80 Dialyzer, a dialyzing solution with a standard electrolytes composition. The dialysis generator will be placed outside of the MRI examination room. The dialysis lines will pass through a wave guide to connect patients positioned on the bed of the MRI. A suitably trained nurse will proceed to the cannulation of the fistula, the connection of the catheter, and the monitoring of the clinical tolerance of the session.
Primary Outcome Measure Information:
Title
Change in phosphate intracellular concentration
Description
Measurement of phosphate intracellular concentration evolution during a 4 hours hemodialysis (HD) session using phosphorus magnetic resonance spectroscopy.
Time Frame
Baseline, at start of HD, every 160 seconds during HD, at the end of HD and 30 minutes after HD
Secondary Outcome Measure Information:
Title
Change in ATP intracellular concentration
Description
Measurement of ATP intracellular concentration evolution during a 4 hours HD session using phosphorus magnetic resonance spectroscopy.
Time Frame
Baseline, at start of HD, every 160 seconds during HD, at the end of HD and 30 minutes after HD
Title
Change in intracellular pH
Description
Measurement of intracellular pH evolution during a 4 hours HD session using phosphorus magnetic resonance spectroscopy. Intracellular pH will be calculated using the Henderson-Hasselbach formula: Ph = 6.75 + log (δ-3.27)/(5.69-δ), with δ being the difference (in parts per million) between inorganic phosphate (Pi) and phosphocreatine (PCr) resonance frequencies.
Time Frame
Baseline, at start of HD, every 160 seconds during HD, at the end of HD and 30 minutes after HD
Title
Change in phosphatemia
Description
Measurement of intracellular pH evolution during a 4 hours HD session using phosphorus magnetic resonance spectroscopy. Intracellular pH will be calculated using the Henderson-Hasselbach formula: Ph = 6.75 + log (δ-3.27)/(5.69-δ), with δ being the difference (in parts per million) between Pi (inorganic phosphate) and PCr (phosphocreatine) resonance frequencies.
Time Frame
At start of HD, every 15 minutes during first hour of HD, then every hour during HD, at the end of HD and 30 minutes after HD
Title
Calcium balance
Description
Calcium balance will be measured using the formula: (Cae - Cab)(Ve - UF)+(Cae * UF), where Cae is the calcium in the effluent, Cab is the calcium in the dialysis solution, Ve is the volume of effluent, and UF is the ultrafiltration.
Time Frame
At the end of a 4 hours HD session

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
80 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Patient suffering from end-stage renal disease, treated by chronic hemodialysis since at less 6 months Phosphatemia (at the start of the session) ≥ 1,5 mmol/L and ≤ 3 mmol/L written consent signed Exclusion Criteria: Major subject protected by law Prisoners or subjects who are involuntarily incarcerated Denutrition (weight loss ≥ 5 kg in one months/10 kg in 6 months, Body Mass Index (BMI) ≤ 21 kg/m2, albuminemia ≤ 35 g/L) Obesity (BMI ≥ 30 kg/m2) Phosphatemia at the start of the dialysis < 1,5 mmol/L or > 3 mmol/L Secondary hyperparathyroidism with parathormone (PTH) ≥ 1000 pg/mL Adynamic osteopathy (PTH ≤ 50 pg/mL) Hypoparathyroidism with a history of parathyroidectomy Hemoglobin ≤ 100 g/L Contraindication to heparin Temporary vascular access Contraindication to resonance magnetic spectroscopy (pacemaker or insulin pump, metallic valvular prosthesis, valvular prosthesis not compatible with resonance magnetic spectroscopy, dental appliance, intracerebral clip, claustrophobic subject). Simultaneous participation to another research protocol Patient not affiliated to a social security system
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Laurent JUILLARD, MD, PhD
Organizational Affiliation
Hospices Civils de Lyon
Official's Role
Principal Investigator
Facility Information:
Facility Name
Service de Néphrologie Pavillon P, Hôpital E. Herriot
City
Lyon
ZIP/Postal Code
69003
Country
France

12. IPD Sharing Statement

Plan to Share IPD
No
Citations:
PubMed Identifier
33093193
Citation
Chazot G, Lemoine S, Kocevar G, Kalbacher E, Sappey-Marinier D, Rouviere O, Juillard L. Intracellular Phosphate and ATP Depletion Measured by Magnetic Resonance Spectroscopy in Patients Receiving Maintenance Hemodialysis. J Am Soc Nephrol. 2021 Jan;32(1):229-237. doi: 10.1681/ASN.2020050716. Epub 2020 Oct 22.
Results Reference
derived

Learn more about this trial

Intracellular Phosphate Concentration Evolution During Hemodialysis by MR Spectroscopy

We'll reach out to this number within 24 hrs